6-异丙基烟酸甲酯 | 84625-02-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-异丙基烟酸甲酯
• 英文名称: methyl 6-isopropylnicotinate
• 英文别名: methyl 6-propan-2-ylpyridine-3-carboxylate
• CAS: 84625-02-5
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: IAPDOIWRTJTAJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-异丙基烟酸甲酯 在 盐酸 作用下， 以 水 为溶剂， 反应 16.0h， 以95%的产率得到6-异丙基烟酸盐酸盐
  参考文献：
  名称：

  Novel S1P₁ Receptor Agonists − Part 3: From Thiophenes to Pyridines

  摘要：

  In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P(1) agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P(1) agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P(1) agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P(1), and S1P(3) receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

  DOI：

  10.1021/jm4014696
• 作为产物：
  描述：

  methyl 6-(prop-1-en-2-yl)nicotinate 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以35%的产率得到6-异丙基烟酸甲酯
  参考文献：
  名称：

  用 ArBpin 试剂对杂芳鎓盐进行脱芳构化。单麻碱全合成中的应用

  摘要：

  开发了铑催化的芳基和杂芳基硼频哪醇酯与吡啶鎓和喹啉鎓盐的对映选择性加成，用于合成对映富集的二氢杂芳烃。该方法能够以高产率和 ee 合成 2-杂芳基取代的二氢吡啶，这为获得单麻生物碱提供了有效的合成途径。

  DOI：

  10.1021/acs.orglett.2c00976

文献信息

• JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
  申请人：GOODACRE SIMON CHARLES

  公开号：US20100317643A1

  公开（公告）日：2010-12-16

  The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R 1 , R 2 , R 4 and R 5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof

  这项发明提供了公式I的化合物，其立体异构体或药学上可接受的盐，其中A、B、D、R1、R2、R4和R5在此处被定义，包括公式I化合物的药物组合物以及其使用方法
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：CASTRO Alfredo C.

  公开号：US20130053362A1

  公开（公告）日：2013-02-28

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

  本文描述了调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的治疗方法，包括PI3激酶活性的化合物、药物组合物和治疗方法。
• SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS
  申请人：Frackenpohl Jens

  公开号：US20140080704A1

  公开（公告）日：2014-03-20

  The invention relates to substituted vinyl- and alkynylcyclohexenols of the general formula (I) and salts thereof where the R 1 , R 2 , R 3 , R 4 , R 5 , [X—Y] and Q radicals are each as defined in the description, to processes for preparation thereof and to the use thereof for enhancing stress tolerance in plants with respect to abiotic stress, and/or for increasing plant yield.

  该发明涉及通式（I）中的取代乙烯基和炔基环己烯醇及其盐，其中R1、R2、R3、R4、R5、[X—Y]和Q基团如描述中所定义，以及其制备方法和用途，用于增强植物对非生物胁迫的抗逆性，和/或增加植物产量。
• [EN] CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS<br/>[FR] ENTITÉS CHIMIQUES, COMPOSITIONS ET PROCÉDÉS
  申请人：INTELLIKINE INC

  公开号：WO2009088986A1

  公开（公告）日：2009-07-16

  Chemical entities that modulate PD kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

  本文描述了调节PD激酶活性的化学实体，含有这些化学实体的药物组合物，以及使用这些化学实体治疗与P13激酶活性相关的疾病和症状的方法。
• Spiro Compounds As NPY Y5 Receptor Antagonists
  申请人：Biagetti Matteo

  公开号：US20090203705A1

  公开（公告）日：2009-08-13

  The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R is an aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C1-C4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; Z 1 is H, C 1 -C 4 alkyl or F; Z is CH 2 , CH(C 1 -C 4 alkyl), C(C 1 -C 4 alkyl) 2 or a bond; A is a 6-10 membered aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; or —C(═O)—X; or —O(CH 2 ) 0-1 R 1 ; B is hydrogen or is a 5-6 membered heteroaryl, or a 4-6 membered heterocycle, or phenyl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, hydroxyl, cyano; A and B being linked via any atom; R 1 is —(C 1 -C 4 )alkyl(C 1 -C 4 )alkoxy; or C 3 -C 8 cycloalkyl; or R 1 is an aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; or R 1 is a 4-6 membered heterocycle, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; X is OR 2 or NR 3 R 4 ; R 2 is C 1 -C 4 alkyl; R 3 is hydrogen or together with R 4 and the nitrogen form a 5-6 saturated membered ring; R 4 is C 3 -C 8 cycloalkyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.

  本发明涉及式(I)的新化合物或其药学上可接受的盐，其中R是芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；Z1是H、C1-C4烷基或F；Z是CH2、CH(C1-C4烷基)、C(C1-C4烷基)2或键；A是一个6-10成员芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基或—C(═O)—X取代；或—O(CH2)0-1R1；B是氢或是一个5-6成员杂芳基、或一个4-6成员杂环、或苯基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、羟基、氰基取代；A和B通过任何原子连接；R1是—(C1-C4)烷基(C1-C4)氧基；或C3-C8环烷基；或R1是一个芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；或R1是一个4-6成员杂环，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；X是OR2或NR3R4；R2是C1-C4烷基；R3是氢或与R4和氮一起形成一个5-6饱和成员环；R4是C3-C8环烷基；它们的制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们作为NPY Y5受体拮抗剂和用于治疗和/或预防暴饮暴食等进食障碍的药物的用途。